1. Home
  2. CMND vs AEMD Comparison

CMND vs AEMD Comparison

Compare CMND & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clearmind Medicine Inc.

CMND

Clearmind Medicine Inc.

HOLD

Current Price

$1.82

Market Cap

2.6M

Sector

Health Care

ML Signal

HOLD

Logo Aethlon Medical Inc.

AEMD

Aethlon Medical Inc.

HOLD

Current Price

$0.68

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMND
AEMD
Founded
2017
1984
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
2.1M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
CMND
AEMD
Price
$1.82
$0.68
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
215.0K
196.1K
Earning Date
03-12-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$0.51
52 Week High
$4.66
$5.89

Technical Indicators

Market Signals
Indicator
CMND
AEMD
Relative Strength Index (RSI) 34.26 24.92
Support Level $1.74 $0.64
Resistance Level $2.76 $0.83
Average True Range (ATR) 0.16 0.12
MACD -0.10 0.01
Stochastic Oscillator 0.58 6.47

Price Performance

Historical Comparison
CMND
AEMD

About CMND Clearmind Medicine Inc.

Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.

About AEMD Aethlon Medical Inc.

Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.

Share on Social Networks: